AA
GRCL

AlphaCentric Advisors’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

AlphaCentric Advisors’s Portfolio GRCL Stock Details GRCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-17,000
Closed -$236K – 282
2021
Q3 		$236K Buy
+17,000
New +$201K 0.06% 105
2021
Q2 		– Sell
-19,000
Closed -$293K – 246
2021
Q1 		$293K Buy
+19,000
New +$448K 0.1% 75

Other funds holding GRCL

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AlphaCentric Advisors's GRCL Position: Q4 2021 in Review

AlphaCentric Advisors sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q4 2021, closing a stake of 17,000 shares — an estimated $236K sold.

AlphaCentric Advisors first reported a position in GRCL in Q1 2021 and held it in 2 quarters. The position peaked at $293K in Q1 2021. 35 funds tracked by Wall St. Rank hold GRCL as of Q4 2021.

  • AlphaCentric Advisors reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q4 2021 after selling out during the quarter.
  • AlphaCentric Advisors sold 17,000 Gracell Biotechnologies Inc. American Depositary Shares shares in Q4 2021, an estimated $236K.
  • AlphaCentric Advisors first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q1 2021 and held it in 2 quarters.
  • AlphaCentric Advisors's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $293K in Q1 2021.
  • 35 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q4 2021.

Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.